Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 14 of the 28 sources its claims cite were checked for support.
Abstract
Histone H3 lysine(27)-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas. We established a Drosophila animal model for the pathogenic histone H3K27M mutation and show that its overexpression resembles polycomb repressive complex 2 (PRC2) loss-of-function phenotypes, causing derepression of PRC2 target genes and developmental perturbations. Similarly, an H3K9M mutant depletes H3K9 methylation levels and suppresses position-effect variegation in various Drosophila tissues. The histone H3K9 demethylase KDM3B/JHDM2 associates with H3K9M-containing nucleosomes, and its misregulation in Drosophila results in changes of H3K9 methylation levels and heterochromatic silencing defects. We have established histone lysine-to-methionine mutants as robust in vivo tools for inhibiting methylation pathways that also function as biochemical reagents for capturing site-specific histone-modifying enzymes, thus providing molecular insight into chromatin signaling pathways.
Overview
CoChat Summary
TL;DR
This paper establishes Drosophila models in which histone H3 lysine-to-methionine mutants (H3.3K27M and H3.3K9M) are overexpressed to inhibit histone methylation pathways in vivo. It shows H3.3K27M phenocopies PRC2 loss and H3.3K9M depletes H3K9 methylation, suppresses position-effect variegation, and captures KDM3B/JHDM2 and SIRT6 as H3K9M-associated factors.
Key findings
- Overexpressing H3.3K27M in Drosophila wing imaginal discs strongly reduces H3K27 methylation and derepresses the PRC2 target gene Ultrabithorax (Ubx), phenocopying E(z) knockdown; RNA-seq shows upregulated Polycomb targets including Ubx, wingless (wg), and Psc, and downregulated Hox/signaling genes including engrailed (en), invected (in), and cubitus interruptus (ci). Tissue-specific Distalless-GAL4 expression causes gross morphological defects and death around eclosion.
- H3.3K9M overexpression globally depletes H3K9 methylation without affecting H3K27 methylation. MudPIT of mononucleosomes from HEK293 cells shows dramatically reduced binding of HP1a (CBX5), HP1β (CBX1), HP1γ (CBX3), CHAF1A/p150, and CHAF1B/p60, and dramatically increased association of KDM3B and SIRT6.
- H3.3K9M suppresses position-effect variegation (PEV) in salivary glands and eye-antenna imaginal discs and derepresses gypsy-lacZ in ovaries. JHDM2 depletion increases H3K9 methylation, whereas JHDM2 overexpression depletes H3K9 methylation and suppresses PEV; Sirt6 RNAi derepresses gypsy-lacZ, but Sirt6 shows no major PEV effects in eye-antenna imaginal discs and salivary glands.
Methods
- Generated UAS-H3.3WT-FLAG-HA, UAS-H3.3K9M-FLAG-HA, and UAS-H3.3K27M-FLAG-HA Drosophila lines and used tissue-specific GAL4 drivers for overexpression in wing imaginal discs, salivary glands, eye-antenna imaginal discs, and ovaries; assays included immunofluorescence, X-Gal PEV staining, and genome-wide RNA-seq.
- HEK293 TRex FLP-in cells with doxycycline-inducible histone constructs were induced with 1 µg/ml doxycycline for 4 days; mononucleosomes were prepared by micrococcal nuclease digestion and anti-FLAG immunoprecipitation from ~7.5×10^8 cells per IP, then analyzed by MudPIT mass spectrometry and dNSAF.
- Main analyses were immunostaining/microscopy, RNA-seq of wing discs, PEV silencing assays, and proteomic interaction profiling of mononucleosomes.
Limitations
- Stated limitations: Not stated in the paper.
- Evident: The H3K27M model relies on GAL4-driven overexpression of tagged H3.3 in Drosophila rather than endogenous heterozygous H3.3K27M as in pediatric gliomas; the paper states the model “may help elucidate” glioma pathogenesis.
- Evident: Biochemical capture of H3K9M interactors was performed in HEK293 cells, while functional H3K9M/JHDM2/Sirt6 assays were in Drosophila; the paper notes that H3K9M mutations in cancers are plausible but as-yet uncharacterized.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 5 Not checked · 27 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Additional histone H3 lysine-to-methionine mutants possess dominant gain-of-function activities [6]”
§ Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling > Abstract
What the sources say
- Supportedcites [6] Lewis PW Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma Science 2013 340 6134 857 61 23539183 PMC3951439 source
The paper reports that H3K9M and H3K36M transgenes reduce methylation at their respective residues. Its concluding passage (labelled Abstract in our copy) describes K-to-M mutations as a gain-of-function mechanism and says mutant histones comprising only a few percent of total histones can prevent global methylation, supporting the claim of dominant activity. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“act in a dominant manner to deplete H3K27 methylation by inhibiting PRC2 methyltransferase activity [5, 6]”
§ Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling > Abstract
What the sources say
- Partly supportedcites [5] Chan KM The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression Genes Dev 2013 27 9 985 90 23603901 PMC3656328 sourceExperimental — accuracy not yet measured
The Results and Discussion report that low-level H3.3K27M expression dramatically reduced endogenous H3K27me2 and H3K27me3, supporting a dominant effect. The paper identifies PRC2 as the H3K27 methyltransferase, but the passages in our copy do not establish that inhibition of its methyltransferase activity is the mechanism. (LLM, conf=0.86)
- Supportedcites [6] Lewis PW Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma Science 2013 340 6134 857 61 23539183 PMC3951439 source
The Abstract (passage 7) reports that H3K27M reduces overall H3K27me3 and inhibits PRC2 enzymatic activity. Passage 6 shows reduced methylation on endogenous wild-type H3 alongside H3K27M, supporting the description of a dominant effect. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Histone H3 lysine27-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.”
- Also stated in: § Abstract · plain
“Single allele mutations of histone H3.3 lysine27-to-methionine (H3.3K27M) occur in a subtype of aggressive pediatric brain cancers [3, 4]”
§ Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling > Abstract
What the sources say
- Not checked — no full text of the sourcecites [3] Schwartzentruber J Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma Nature 2012 482 7384 226 31 22286061 source
- Partly supportedcites [4] Wu G Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas Nat Genet 2012 44 3 251 3 22286216 PMC3288377 sourceExperimental — accuracy not yet measured
The Abstract reports monoallelic p.K27M substitutions in histone H3 genes, including H3F3A (H3.3), in pediatric high-grade gliomas. It says these substitutions suggest a gain-of-function effect, but that further studies are required to determine their functional impact; the citing sentence states gain of function as established. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Histone H3K9me3 serves as a binding substrate for heterochromatin protein 1 (HP1) [9–12]”
§ Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling > Abstract
What the sources say
- Could not verifycites [9] James TC Elgin SC Identification of a nonhistone chromosomal protein associated with heterochromatin in Drosophila melanogaster and its gene Molecular and cellular biology 1986 6 11 3862 72 3099166 PMC367149 sourceExperimental — accuracy not yet measured
Our copy of James & Elgin (1986) consists of the bibliographic header, the abstract (identification of a 19-kDa Drosophila nuclear protein localized by immunofluorescence to alpha, beta and intercalary heterochromatin, its cDNA and gene at 29A) and the reference list; nothing in it addresses histone H3 lysine 9 trimethylation or a methylation-dependent binding mechanism for HP1. Searches for 'histone H3 lysine 9 methylation binding site HP1' and 'methylated DNA histone modification recognition chromodomain' returned only the abstract and reference-list passages (semantic matches, scores ~0.70-0.75), i.e. no passage states or contradicts the claim. The paper identifies the heterochromatin-associated protein itself but says nothing about H3K9me3 as its ligand, so this source cannot support the attributed mechanistic statement. (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [10] Bannister AJ Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain Nature 2001 410 6824 120 4 11242054 source
- Not checked — no full text of the sourcecites [11] Nakayama J Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly Science 2001 292 5514 110 3 11283354 source
- Partly supportedcites [12] Lachner M Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins Nature 2001 410 6824 116 20 11242053 sourceExperimental — accuracy not yet measured
Our copy of James & Elgin (1986) identifies the protein the citing sentence names: the Abstract (p. 3862) describes monoclonal antibodies against a 19-kilodalton nuclear protein of D. melanogaster whose antigen is localized by immunofluorescence to the alpha, beta and intercalary heterochromatic regions, plus the cloning and mapping of its gene to 29A on 2L — i.e., the original HP1 identification. However, no passage in our copy (Abstract, or the reference lists pp. 3870–3872 returned by searches for 'HP1 / methylated histone H3 lysine 9' and 'protein binds methylated DNA heterochromatin association mechanism') addresses histone H3 K9 methylation as a binding substrate; the binding described is of the protein fraction 'tightly binding to DNA'. The H3K9me3-recognition half of the claim is therefore not supported by this source, which can stand only as the identification of HP1 itself. (LLM, conf=0.68)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“thus phenocopying knockdown of the catalytic PRC2 subunit E(z) (fig. S2)”
- Also stated in: § Abstract · plain
“show that its overexpression resembles Polycomb repressive complex 2 (PRC2) loss-of-function phenotypes”
§ Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
27 more claims
Create a free account to see all 44 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, our previous biochemical purifications of mono-nucleosomes containing H3K27M did not show any preferential enrichment for PRC2 subunits5.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Expression of the histone mutant is accompanied by a reduction in the levels of Polycomb Repressive Complex 2 (PRC2) mediated H3K27 trimethylation (H3K27me3) and this is purported to be a driving event of DIPG oncogenesis4,5.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“As shown by our group and others, H3K27M expression is associated with increased levels of H3K27ac4,5 (Fig. 1D).”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [5]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These results support the increased association of acetyl-binding bromodomain proteins to H3K27M containing nucleosomes5, and prompted us to investigate the role of these proteins in DIPG cells.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [5]
Experimental — accuracy not yet measured
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347
Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C., & Kouzarides, T. (2001) · Nature · doi:10.1038/35065138 · Cited by 2,903
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., & Jenuwein, T. (2001) · Nature · doi:10.1038/35065132 · Cited by 2,868
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631 · cited 2×
“3K27M) occur in a subtype of aggressive pediatric brain cancers [3, 4], and act in a dominant manner to deplete H3K27 methylation by inhibiting PRC2 methyltransferase activity [5, 6].”
BackgroundLoss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability
Peters, A. H. F. M., O'Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Schöfer, C., Weipoltshammer, K., Pagani, M., Lachner, M., Kohlmaier, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00542-6 · Cited by 1,766
Role of Histone H3 Lysine 9 Methylation in Epigenetic Control of Heterochromatin Assembly
Nakayama, J.-I., Rice, J. C., Strahl, B. D., Allis, C. D., & Grewal, S. I. S. (2001) · Science · doi:10.1126/science.1060118 · Cited by 1,739
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345 · cited 4×
“3K9M constructs with a Cterminal FLAG-HA tag [6] for tissue-specific overexpression in Drosophila.”
BackgroundMethodInfluentialShilatifard, A. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-051710-134100 · Cited by 1,091 · cited 2×
“Histone proteins constitute the core of the eukaryotic chromatin [1].”
BackgroundSelf-citationHeterochromatin and Epigenetic Control of Gene Expression
Grewal, S. I. S., & Moazed, D. (2003) · Science · doi:10.1126/science.1086887 · Cited by 1,065
Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
Behjati, S., Tarpey, P. S., Presneau, N., Scheipl, S., Pillay, N., Van Loo, P., Wedge, D. C., Cooke, S. L., Gundem, G., Davies, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2814 · Cited by 854
Schotta, G., Ebert, A., Krauss, V., Fischer, A., Hoffmann, J., Rea, S., Jenuwein, T., Dorn, R., & Reuter, G. (2002) · The EMBO Journal · doi:10.1093/emboj/21.5.1121 · Cited by 714
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression
Chan, K.-M., Fang, D., Gan, H., Hashizume, R., Yu, C., Schroeder, M., Gupta, N., Mueller, S., James, C. D., Jenkins, R., et al. (2013) · Genes & Development · doi:10.1101/gad.217778.113 · Cited by 707
James, T. C., & Elgin, S. C. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.11.3862 · Cited by 643
HP1 and the dynamics of heterochromatin maintenance
Maison, C., & Almouzni, G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1355 · Cited by 623 · cited 1×
“Trimethylation of histone H3 lysine 9 (H3K9me3) by Supressor of variegation 3-9 (Su(var)3-9) proteins is a hallmark of heterochromatin [8].”
BackgroundEissenberg, J. C., James, T. C., Foster-Hartnett, D. M., Hartnett, T., Ngan, V, & Elgin, S. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.24.9923 · Cited by 588
Self-citationPosition-Effect Variegation, Heterochromatin Formation, and Gene Silencing in Drosophila
Elgin, S. C. R., & Reuter, G. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a017780 · Cited by 499 · cited 9×
“Reduced dosage of Drosophila HP1 and Su(var)3-9 results in suppression of position-effect variegation (PEV) [19–21].”
BackgroundInfluentialHistone modification: cause or cog?
Henikoff, S., & Shilatifard, A. (2011) · Trends in Genetics · doi:10.1016/j.tig.2011.06.006 · Cited by 482
Self-citationZhang, Y., Wen, Z., Washburn, M. P., & Florens, L. (2010) · Analytical Chemistry · doi:10.1021/ac9023999 · Cited by 385
Self-citationTaddei, A., Maison, C., Roche, D., & Almouzni, G. (2001) · Nature Cell Biology · doi:10.1038/35055010 · Cited by 361
Eissenberg, J. C., Morris, G. D., Reuter, G., & Hartnett, T. (1992) · Genetics · doi:10.1093/genetics/131.2.345 · Cited by 315
Self-citationSET for life: biochemical activities and biological functions of SET domain-containing proteins
Herz, H.-M., Garruss, A., & Shilatifard, A. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.09.004 · Cited by 314
Self-citationHeterochromatin Dynamics in Mouse Cells
Murzina, N., Verreault, A., Laue, E., & Stillman, B. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80204-x · Cited by 300 · cited 1×
“3K9M mononucleosomes, as was interaction of the HP1associated proteins chromatin assembly factor 1a (CHAF1A/p150) [17, 18] and CHAF1B/p60 (Fig.”
BackgroundA Histone Mutant Reproduces the Phenotype Caused by Loss of Histone-Modifying Factor Polycomb
Pengelly, A. R., Copur, Ö., Jäckle, H., Herzig, A., & Müller, J. (2013) · Science · doi:10.1126/science.1231382 · Cited by 297
Sarot, E., Payen-Groschêne, G., Bucheton, A., & Pélisson, A. (2004) · Genetics · doi:10.1534/genetics.166.3.1313 · Cited by 251 · cited 2×
“The gypsy-lacZ construct is normally silenced in almost all follicle cells but is upregulated upon loss of heterochromatin function [24].”
BackgroundHandler, D., Olivieri, D., Novatchkova, M., Gruber, F. S., Meixner, K., Mechtler, K., Stark, A., Sachidanandam, R., & Brennecke, J. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.308 · Cited by 190
Quivy, J.-P., Gérard, A., Cook, A. J. L., Roche, D., & Almouzni, G. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1470 · Cited by 148
KDM3B Is the H3K9 Demethylase Involved in Transcriptional Activation of lmo2 in Leukemia
Kim, J.-Y., Kim, K.-B., Eom, G. H., Choe, N., Kee, H. J., Son, H.-J., Oh, S.-T., Kim, D.-W., Pak, J. H., Baek, H. J., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00133-12 · Cited by 115 · cited 1×
“KDM3B was recently characterized as a member of the JumonjiC domain-containing histone demethylases that shows specificity toward H3K9 and is involved gene activation in leukemia cells [25, 26], however, a role for this factor in PEV has not been reported.”
BackgroundSchaaf, C. A., Misulovin, Z., Gause, M., Koenig, A., Gohara, D. W., Watson, A., & Dorsett, D. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003560 · Cited by 114
Developmental regulation of heterochromatin-mediated gene silencing in Drosophila
Lu, B. Y., Ma, J., & Eissenberg, J. C. (1998) · Development · doi:10.1242/dev.125.12.2223 · Cited by 88
Self-citationDevelopmental timing and tissue specificity of heterochromatin-mediated silencing
Lu, B. Y., Bishop, C. P., & Eissenberg, J. C. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00474.x · Cited by 84 · cited 2×
“chromosomal heterochromatin [22, 23], overexpression of H3.”
Self-citationBrauchle, M., Yao, Z., Arora, R., Thigale, S., Clay, I., Inverardi, B., Fletcher, J., Taslimi, P., Acker, M. G., Gerrits, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060549 · Cited by 79 · cited 1×
“KDM3B was recently characterized as a member of the JumonjiC domain-containing histone demethylases that shows specificity toward H3K9 and is involved gene activation in leukemia cells [25, 26], however, a role for this factor in PEV has not been reported.”
BackgroundHerz, H.-M., Mohan, M., Garrett, A. S., Miller, C., Casto, D., Zhang, Y., Seidel, C., Haug, J. S., Florens, L., Washburn, M. P., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06503-11 · Cited by 75
Self-citationThe Methyltransferase Activity of Clr4Suv39h Triggers RNAi Independently of Histone H3K9 Methylation
Gerace, E. L., Halic, M., & Moazed, D. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.07.017 · Cited by 70 · cited 1×
“Indeed, studies in fission yeast point to H3K9 methylation-independent functions for the Su(var)3-9 homolog Clr4 in chromatin silencing [16].”
BackgroundGeneration and Analysis of Multidimensional Protein Identification Technology Datasets
Swanson, S. K., Florens, L. A., & Washburn, M. P. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-493-3_1 · Cited by 30
Self-citationChromatin in the Nuclear Landscape
Beck, D. B., Bonasio, R., Kaneko, S., Li, G., Li, G., Margueron, R., Oda, H., Sarma, K., Sims, R. J., Son, J., et al. (2010) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2010.75.052 · Cited by 27
Cited by
Epigenetic modifications of histones in cancer
Zhao, Z., & Shilatifard, A. (2019) · Genome Biology · doi:10.1186/s13059-019-1870-5 · Cited by 552
Self-citationThe roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Epigenetic balance of gene expression by Polycomb and COMPASS families
Piunti, A., & Shilatifard, A. (2016) · Science · doi:10.1126/science.aad9780 · Cited by 524
Self-citationTherapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
Piunti, A., Hashizume, R., Morgan, M. A., Bartom, E. T., Horbinski, C. M., Marshall, S. A., Rendleman, E. J., Ma, Q., Takahashi, Y.-H., Woodfin, A. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4296 · Cited by 445
Self-citationSolomon, D. A., Wood, M. D., Tihan, T., Bollen, A. W., Gupta, N., Phillips, J. J. J., & Perry, A. (2016) · Brain Pathology · doi:10.1111/bpa.12336 · Cited by 433
Metadata
- Authors
- Herz, H.-M., Morgan, M., Gao, X., Jackson, J., Rickels, R., Swanson, S. K., Florens, L., Washburn, M. P., Eissenberg, J. C., & Shilatifard, A.
- Affiliations
- Stowers Institute for Medical Research (US)
- Saint Louis University (US)
- Corresponding author
- Herz, Hans-Martin
- Morgan, Marc
- Shilatifard, Ali
- Venue
- Science
- Published
- 2014-08-29
- Volume
- 345
- Issue
- 6200
- Pages
- 1065-1070
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4508193
- OpenAlex
- W2058818049
- Semantic Scholar
- cc46ffc8cf13a6bb6a94dcd9d3e80522bf04f88d
- Cited by
- 199
- References
- 37
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 12 · 2023: 12 · 2022: 14 · 2021: 20 · 2020: 20 · 2019: 23 · 2018: 17 · 2017: 27 · 2016: 17 · 2015: 11 · 2014: 4
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- H3K27M mutation, pediatric glioma, polycomb repressive complex 2, position effect variegation, heterochromatin silencing, H3K9 demethylation, histone methylation, Drosophila model
- MeSH terms
- Animals, Chromatin, Disease Models, Animal, Drosophila melanogaster, Glioma, Heterochromatin, Histones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.